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ABSTRACT
Antibiotics offer an efﬁcient means for managing diseases caused by bacterial pathogens. However,
antibiotics are typically broad spectrum and they can indiscriminately kill beneﬁcial microbes in
body habitats such as the gut, deleteriously affecting the commensal gut microbiota. In addition,
many bacteria have developed or are developing resistance to antibiotics, which complicates
treatment and creates signiﬁcant challenges in clinical medicine. Therefore, there is a real and
urgent medical need to develop alternative antimicrobial approaches that will kill speciﬁc problem-
causing bacteria without disturbing a normal, and often beneﬁcial, gut microbiota. One such
potential alternative approach is the use of lytic bacteriophages for managing bacterial infections,
including those caused by multidrug-resistant pathogens. In the present study, we comparatively
analysed the efﬁcacy of a bacteriophage cocktail targeting Escherichia coli with that of a broad-
spectrum antibiotic (ciproﬂoxacin) using an in vitro model of the small intestine. The parameters
examined included (i) the impact on a speciﬁc, pre-chosen targeted E. coli strain, and (ii) the impact
on a selected non-targeted bacterial population, which was chosen to represent a deﬁned microbial
consortium typical of a healthy small intestine. During these studies, we also examined stability of
bacteriophages against various pH and bile concentrations commonly found in the intestinal tract
of humans. The bacteriophage cocktail was slightly more stable in the simulated duodenum
conditions compared to the simulated ileum (0.12 vs. 0.58 log decrease in phage titers,
respectively). It was equally effective as ciproﬂoxacin in reducing E. coli in the simulated gut
conditions (2–3 log reduction), but had much milder (none) impact on the commensal, non-
targeted bacteria compared to the antibiotic.
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1. Introduction
Antibiotics are a type of antimicrobial drug used for
either killing (bactericidal antibiotics; e.g., vancomy-
cin) or inhibiting the growth (bacteriostatic antibiot-
ics; e.g., tetracycline) of microorganisms. The
discovery of antibiotics in the ﬁrst half of the 20th cen-
tury revolutionized medicine as it allowed treatment
of bacterial infections that were essentially untreatable
during the pre-antibiotic era; in addition to saving
countless lives, it also fostered the development of
many sophisticated medical procedures (e.g., organ
transplantation surgeries) that were previously not
possible due to, in part, the inability to manage bacte-
rial infections that are unavoidable during such
surgical procedures. However, extensive use (and
sometimes misuse) of antibiotics since their discovery
has also led to an emergence of antibiotic-resistant
bacteria – bacteria that cannot be killed by commonly
available antibiotics, and in some cases by any avail-
able antibiotics; e.g., multiple drug resistance (MDR),
extensively drug resistant (XDR), and pan-drug-resis-
tant (PDR) bacteria.
This emergence of drug-resistance is a very serious
problem in modern medicine, which imposes a signiﬁ-
cant social and economic burden on the society,
including the loss of lives.1,2 The problem is further
exacerbated by the fact that most antibiotics are
broad-spectrum. In practice this means that in addi-
tion to targeting disease-causing bacteria, antibiotic
therapy can cause substantial collateral damage to the
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human microbiota by killing many other, non-tar-
geted, and often beneﬁcial bacteria. This collateral
effect can, and often does, lead to dysbiosis,3,4 further
promoting the emergence of resistant bacteria (via
selective pressure), and may also facilitate horizontal
transfer of resistance genes.5,6 Moreover, growing evi-
dence suggests that microbiota disturbance caused by
antibiotics may promote various other health prob-
lems such as obesity, asthma, inﬂammatory bowel dis-
ease, and diabetes.1-4 Therefore, there is an increasing
interest to manage infections caused by antibiotic-
resistant pathogens by selectively targeting the dis-
ease-causing bacteria, without disturbing the
commensal microbiota of the human gastrointestinal
(GI) tract. One intriguing concept in that regard is the
use of lytic bacteriophages, to selectively and speciﬁ-
cally kill disease-causing bacteria, including MDR,
XDR, and PDR.
Bacteriophages (or “phages” for short) are bacteria-
infecting viruses. Lytic phages have potent bactericidal
activity against their host bacterial strains. During the
lytic cycle the phage infects the cell, using the cell’s
replication and translation machinery to replicate and
then lyses the cell releasing new phage particles into
the environment. In cases where overwhelming con-
centrations of phage are applied “lysis from without”
might occur as well.7,8 Phages are also very speciﬁc:
they only attack their targeted bacterial hosts, and
they cannot infect human or other eukaryotic cells.
Even within bacterial taxa, and in clear contrast to
broad-spectrum antibiotics, phages usually only lyse
strains or a subgroup of strains within the bacterial
species, making targeted bacterial therapy possible.
Increased presence of Adherent-Invasive Escheri-
chia coli in the ileum has been associated with Ileal
Crohn’s disease (ICD)9-11 and ICD-associated E. coli
has been found to manifest multidrug resistance.12
Therefore, phages targeting these bacteria might be an
alternative for antibiotics and have potential therapeu-
tic ability in ICD management. In order to lyse their
targeted bacteria in the small or large intestine, orally-
administered phages must pass through the harsh
environment of the human GI tract, including the low
pH in the stomach, presence of pancreatic enzymes,
and bile salts in the small intestine.13-15 These factors
may reduce phage viability/stability and render them
less effective or ineffective; yet, despite the long history
of therapeutic use of phages in humans, there is strik-
ing paucity of information on the pharmacokinetics of
bacteriophages when they are administered orally.16-18
Thus, the goal of this study was to start to elucidate
the persistence of bacteriophages in the human GI
tact, by testing a phage cocktail targeting E. coli in a
simulated human small intestinal model system.
During these studies, we also compared the impact of
the phage cocktail vs. a commonly used broad-spec-
trum antibiotic, ciproﬂoxacin, on the levels of E. coli,
and other selected (non-targeted, representative of the
“normal” microbiota) bacteria in the simulated small
intestine system.
2. Materials and methods
2.1. Small intestine model system: Consortium
of microorganisms and growth conditions
To simulate a normal, healthy, small intestine micro-
biome, a consortium of 7 bacterial species were
selected to represent a healthy ileal microbiota19,20
(Table 1). All bacteria were acquired from the Ger-
man Collection of Microorganisms and Cell cul-
tures (DSMZ).21 Strains were propagated in Gifu
Anaerobic Medium (GAM Broth, NISSUI) in an
anaerobic bench (CoyLab, USA), under strictly
anaerobic conditions using an Anaerobic jar
(Merck) together with the AnaeroGen system
(Oxoid). Before each experiment, all strains were
cultured separately in 10 ml GAM broth for the
incubation time optimal for each individual strain
according to.23 After propagation, bacterial cells
were centrifuged for 2 minutes at 4,000 g, the
Table 1. Bacterial strains, their source, culturing time and range on growth media. Taken from {Cieplak:Rpap5xgx}.
Species Strain source Origin Culture time [h] Culture media
Escherichia coli DSM 1058 Human intestine 24 VRB, MCC, GAM
Streptococcus salivarius DSM 20560 Blood 6 M17, GAM
Streptococcus luteinensis DSM 15350 Human isolate 24 M17, GAM
Enterococcus faecalis DSM 20478 Human faeces 24 MCC, GAM
Bacteroides fragilis DSM 2151 Appendix abscess 24 GAM
Veillonella parvula DSM 2008 Human intestine 48 GAM
Flavonifractor plautii DSM 6740 Human faeces 48 GAM
VRB: Violet Red Bile Agar, M17: M17 Agar, MCC: MacConkey Agar and GAM: Gifu Anaerobic Agar.
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supernatant was discarded, and precipitated bacteria
were resuspended in volumes of PBS (pH 7.4) ade-
quate to obtain a ﬁnal concentration of ca. 108
CFU/ml for each strain. After adjusting concentra-
tions, all strains were mixed in an equal ratio and
either used immediately or stored in liquid nitrogen
until future use.
2.2. Bacteriophage preparation
For this pilot study, we speciﬁcally formulated a bacte-
riophage preparation to target one strain from the rep-
resentative ileal consortium: E. coli DSM 1058. For the
phage cocktail, individual monophages were selected
from Intralytix’s bacteriophage collection, based on
their ability to lyse the DSM 1058 strain in the classical
Spot Test assay.22 Various dilutions were used for the
spot test to differentiate between lysis and inhibition
(i.e., low dilutions resulting in plaques were tested as
well). The resulting susceptibility data were analyzed
using the PhageSelectorTM program (proprietary pro-
gram developed by Intralytix) to formulate bacterio-
phage cocktail Ec17B153DK1. The resulting cocktail is
composed of 3 phages (ECML-363, ECML-122 and
ECML-359) each having potent lytic activity against
E. coli DSM 1058. Each component monophage was
propagated separately in their respective E. coli host
strains at 37C, with Multiplicity of infections (MOIs)
ranging from 2 £ 10¡4 to 1 £ 10¡1. Following propa-
gation, each phage was harvested by ﬁltering through
a 0.2-micron ﬁlter and concentrated/buffer exchanged
in a 0.85% saline solution. Following buffer exchange,
the three monophages were combined in approxi-
mately equal concentrations to produce the phage
cocktail Ec17B153DK1. The ﬁnal cocktail was then
sterile ﬁltered through a 0.2-micron ﬁlter and stored
refrigerated (2–8C) until use.
The ability of each of the three phages included in
the Ec17B153DK1 phage cocktail, and the phage cock-
tail itself, was also tested against an additional 607 E.
coli strains (Fig. 1) and against the 6 non-E. coli strains
(Table 1) used in our model system.
2.3. Small intestine in vitro simulation
To simulate passage of phages through the human
small intestine (SI), we used a newly developed
dynamic in vitro model (TSI).23 The TSI consists of 5
reactors with working volumes of 12 ml each. Each
reactor simulates the small intestine of one individual.
Parameters like pH, temperature, and bile salts con-
centration and pancreatic juice were monitored and
Figure 1. Host range of the Ec17B153DK1 component phages against 408 E. coli isolates. Host range and interaction network of the
three monophages (ECML-122, ECML-363, ECML-359) included the Ec17B153DK1 phage cocktail. Phages are depicted as large pink
circles. Results shown are for 408 susceptible E. coli strains (i.e., 199 resistant strains were not included in the chart for simplicity). Each
small circle is an E. coli isolate. The gray lines connecting each phage to bacterial strains indicate the ability to infect and kill that given
E. coli strain based on the Spot Test assay. Bacterial strains killed by more than one phage are grouped towards the canter of the chart.
The graph was generated using proprietary PhageSelectorTM program developed by Intralytix, Inc.
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maintained at physiologically relevant levels during
simulations (4–10 mM bile salts; 40 – 100 U/ml pan-
creatic juice). Both bile salts and pancreatic juice origi-
nated from pigs. Reactors were prepared and run
according to.23 Brieﬂy, before addition of phages to
the reactors, the pH was adjusted and conﬁrmed to be
6.5 at which point 0.5 ml of the phage cocktail (10.81
log PFU/ml) or controls were added to the simulated
small intestines. From there on the whole experiment
is divided into 3 stages: duodenum, jejunum and
ileum, each of them characterized by different condi-
tions. During duodenum passage (2 hours), pH is ele-
vated from 6.5 to 6.8 and pancreatic juice and bile
salts are administrated. During the jejunum stage
(4 hours), pH is raised from 6.8 to 7.2, while bile salts
and small nutrients are re-absorped. Finally, during
the ileum stage the small intestine microbial consor-
tium / E. coli suspension is added and pH is stabilized
at 7.2 during 2 hours as described in detail in.23
2.4. Bacteriophages persistence and impact on E.
coli during small intestine passage
To test the persistence of the phage cocktail during small
intestinal transit, and its efﬁcacy against the targeted E.
coli strain, four TSI reactors were inoculated with 0.5 ml
of the bacteriophage cocktail (10.81 log PFU/ml), in the
last reactor we added saline solution (0.5 ml, 0.9% NaCl)
as control. Simulated small intestinal digestion was car-
ried out as described in.23 Before the ileal step 1 ml of E.
coli suspension (7 log CFU/ml), propagated in a similar
manner as described in section 3.1. was added into each
reactor. Persistence of the phage cocktail was tested
before the duodenum (baseline), after duodenum and
after the ilium stage by determining plaque forming
units (PFU) counts24 in an E. coli host strain grown on
VRB (Violet Red Bile Agar, Sigma-Aldrich) selective
agar media. Efﬁciency of phage cocktail against E. coli
was quantiﬁed at the end of the ileal stage by comparing
bacteria counts before and after the ileal stage in phage-
treated vs. untreated control samples, via colony plate
counts on VRB agar medium.
2.5. Impact of bacteriophage cocktail versus
ciproﬂoxacin on the microbiota
To compare the impact of the bacteriophage cocktail vs.
an antibiotic on the ileal microbiota, a mixture of 7 bac-
terial strains of various spp. (Table 1) was co-incubated
with the phage cocktail, the antibiotic (ciproﬂoxacin),
or water (control), and the impact of each treatment on
the overall bacterial counts was determined by plating
on selective and non-selective substrates. Experiments
were conducted for each preparation and feeding condi-
tion in duplicate. Brieﬂy, 0.5 ml of phage cocktail (10.81
log PFU/ml) was added in two reactors and 0.5 ml of
water was added to the other three reactors, of which
two were also supplemented with 1 ml of ciproﬂoxacin
(500 mg/l in ﬁnal solution). Before the ileal phase of the
experiment, 1 ml of microbial consortia (see Table 1),
and 3 ml of fresh SIF consisting of bile salts and pancre-
atic juice were added to each reactor. After the experi-
ment, samples were taken from each reactor and plated
on the following 4 media, followed by incubation at
37 C for 24 h: (1) VRB for enumeration of E. coli, (2)
M17 Agar (Oxoid) for enumeration of Streptococcus
sp., (3) MacConkey Agar (MCC, Sigma-Aldrich) for
enumeration of Enterococcus feacalis, and (4) Gifu
Anaerobic Agar (GAM, NISSUI) where all microbes
from the small intestine consortium (Table 1) can grow.
2.6. Statistical analysis
All statistical analyses were performed using the Prism
7 v 7.0b software (GraphPad). Differences between
groups were calculated using one-way ANOVA with
Tukey’s multiple comparisons test, with a single pooled
variance. Signiﬁcance was determined at P<0.05 level.
3. Results
3.1. Bacteriophage preparation: Target range
and speciﬁcity
Bacteriophage cocktail Ec17B153DK1 was speciﬁcally
formulated for this study. It was speciﬁcally designed to
lyse E. coli DSM 1058, which is one of 7 strains included
in the small intestine model consortia. Each of the three
phages included in the Ec17B153DK1 cocktail was capa-
ble of lysing DSM 1058. We also tested monophages in
the cocktail for their ability to lyse a panel of an addi-
tional 607 E. coli isolates, using the classical Spot Test
assay; the cocktail lysed 408 (67%) of 607 E. coli strains
examined (including DSM 1058) (Fig. 1). The cocktail
was also tested against six strains of the non-targeted
consortia included in our model system (Table 1), using
the same Spot Test assay. None of the six non-E. coli
strains included in our TSI model were susceptible to the
cocktail (data not shown).
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3.2. Bacteriophage stability in the small intestine
in vitro model
We tested persistence of phages in the small intestine
in the presence of Escherichia coli and in two different
feeding conditions mimicking either a “fasted” small
intestine (i.e., mimicking conditions before a meal;
bile salts D 4mM; pancreatic Juice D 40 U/ml) or a
“fed” small intestine (i.e., mimicking conditions after a
meal; bile salts D 10 mM; pancreatic juice D 100 U/
ml). The number of phages did not change signiﬁ-
cantly (P>0.05) under the fasted conditions for either
the duodenum (10.59§ 0.06 log PFU/ml) or the ileum
simulated conditions remaining at ca. 10.32 § 0.17 log
PFU/ml). In the fed state, the concentration of phages
remained stable until the end of duodenum stage
(10.76 § 0.14 log PFU/ml) and then slightly decreased
at the end of the ileum stage (from 10.81 log PFU/ml
to 10.17 log PFU/ml (§0.35); P D 0.048),.
3.3. Impact of the bacteriophage cocktail vs.
antibiotic on the levels of E. coli in the small
intestine in vitro model
The ability of our phage cocktail to reduce the levels of
the targeted E. coli strain in the model system was eval-
uated by inoculating 1 ml of E. coli culture into the sim-
ulated ileal section (both fed and fasted) of the small
intestine, and adding either the phage cocktail or sterile
water (as control). For both fasted and fed conditions,
we observed a signiﬁcant decrease in E. coli cell counts
(Fig. 2 Fasted: P <0.01, Fed: P <0.01). Speciﬁcally,
addition of bacteriophages reduced the levels of the tar-
geted E. coli cells by ca. 2.5 log (99,5%) in both fed and
fasted conditions. There was no reduction of E. coli lev-
els in the phage-untreated, control group; in fact, the E.
coli population slightly increased in control samples
under the fed conditions (Fig. 2). The reduction in the
E. coli population was slightly more pronounced under
the fed condition compared to fasted conditions,
although the difference was not statistically signiﬁcant.
3.4. Impact of bacteriophage cocktail vs. antibiotic
on the ileal bacterial community
The impact of a broad-spectrum antibiotic (ciproﬂoxa-
cin) on the ileal bacterial consortia was compared to
that of the bacteriophage cocktail (Fig. 3). The phage
cocktail and ciproﬂoxacin showed similar efﬁcacy in
reducing E. coli, each yielding on average a 2.5 log
(99.5%) reduction (Fig. 3). However, the phage cocktail
was highly speciﬁc towards targeted E. coli species and
did not signiﬁcantly reduce any of the other species of
the ileal consortium (p>0.05 for both Fasted state and
Fed state) (Fig. 3). In contrast, ciproﬂoxacin reduced
Figure 2. Lytic activity of the bacteriophage cocktail against targeted bacteria in the TSI model. Testing the lytic activity of the phage
cocktail in two feeding conditions (fasted, fed). E. coli culture was added to the reactors at the ileum stage (ca. 7 log CFU/mL). The data
shown are for the ileum compartment. The dotted line indicates the number of E. coli before treatment with the bacteriophage cocktail.
All experiments were performed in triplicates (n D 3). P < 0.05 – signiﬁcant. P < 0.01 – highly signiﬁcant.
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counts of all other bacteria on average of 1 log (90%)
on all growth media for both fed and fasted states
(Fig. 3).
4. Discussion
4.1. Phages retain signiﬁcant infectivity after
passage through simulated small intestines
Most phage treatments are administrated orally,
although phages have been applied to humans ther-
apeutically via various other routes as well, includ-
ing auricular, intravesical, intrapulmonary, rectal,
topical, and intravenous (reviewed in25). For oral
administration, it is generally believed that phages
are deleteriously impacted by the low acidity of the
stomach; hence, many oral applications involved
administering phages together with bicarbonate
water (to neutralize stomach acidity) or in a special
enteric formulations (gel caps or tablets) that pro-
vide protection during passage through the acidic
stomach environment (pH ranging from 1 – 2 up
to 4 – 5) by dissolving and releasing phages only
during less acidic sections of the intestinal track,
such as the small intestine (pH 6 – 7.4), caecum
(pH 5.7) or the rectum (pH 6.7).26 However, rigor-
ous data on the persistence of phages in various GI
tract sections are not available, and it is not well
established how various physiological conditions
Figure 3. Impact of ciproﬂoxacin and bacteriophage cocktail on simulated small intestine microbiota in fasted (A) and fed (B) conditions
(7 different bacterial spp., Table 1) in the TSI model. Survival of different bacteria species from the simulated small intestinal microbiota
was tested on four different culturing media: Violet Red Bile Agar (VRB) for enumeration of E. coli, M17 Agar (M17) for enumeration of
Streptococcus sp., MacConkey Agar (MCC) for enumeration of E. faecalis, and Gifu Anaerobic Agar (GAM) where all species from small
intestinal consortium can be cultivated. All experiments were performed in duplicate (n D 2). P < 0.05 – signiﬁcant (difference
between bacteriophage or ciproﬂoxacin treatment compared to control samples). P < 0.01 – highly signiﬁcant (difference between
bacteriophage or ciproﬂoxacin treatment compared to control samples).
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that impact gut parameters (e.g., consumption of
foods) may further inﬂuence this.
To begin addressing these questions, a TSI in
vitro system23 was used to determine phage stabil-
ity and efﬁcacy by simulating various sections of
the small intestine (duodenum, jejunum or ileum)
both in “fasted” or “fed” conditions. In general, the
varying environmental conditions (pH, bile) during
simulated small intestinal passage did not affect the
stability of the phages. There was slight decrease in
phage titers in the ileum under the fed conditions;
however, the reduction was relatively minor and
the phage cocktail was still able to signiﬁcantly
reduce E. coli levels in our in vitro system. Speciﬁ-
cally, the phage cocktail reduced E. coli levels by
the same ca. 2.5 log both in fed and fasted condi-
tions. This study’s results diverge from the study
by Ma et al., who reported larger (1.29 and 1.67
log units, respectively) loss of Salmonella phage
Felix O1) titers in 1% and 2% bile solution.27 The
negative impact of bile salts on phage viability has
been reported by some other authors as well28-30;
however, the topic is still not fully understood as
other investigators – and this study – suggest that
phages can be fairly stable and remain infectious
when exposed to bile salts ranging from 4–
10 mM).31 It is possible that the phage viability
will be more profoundly reduced in vivo due to
many additional factors (e.g., intestinal peristalsis,
more complex microbiota, various diets, etc.) that
may deleteriously impact phage particles in the GI
tract. Also, different bacteriophages can have differ-
ent stability against bile salts, pH, etc. Elucidating
the underlying mechanisms could prove to be a fer-
tile area for subsequent investigations, and the
results could offer important insights into the basic
phage biology as well as for designing optimal
phage preparations for various oral phage therapy
applications.,
4.2. Bacteriophages preserve representative small
intestine microbiome
In our studies, the phage preparation and ciproﬂoxa-
cin reduced the E. coli levels in our in vitro model sys-
tem by the same ca. 2.5 log. However, the two
antimicrobials had very different impact on the non-
targeted microbiota. Speciﬁcally, phage administration
had no detectable impact on the six non-E. coli
bacterial species included in our model system;
whereas, ciproﬂoxacin reduced the levels of all bacteria
in the consortium (Fig. 3). Short and long-term use of
antibiotics could lead to a wide range of undesired
effects, such as diarrhea, dysbioses, and other indirect
deleterious effects such as obesity or colitis. These del-
eterious effects are usually due to the antibiotic-caused
non-speciﬁc reduction of beneﬁcial gut microbes, and
the associated general perturbance in the gut micro-
biota. In this context, ciproﬂoxacin is one of the most
widely used antibiotics to treat E. coli infections in
the gut.32,33 Unfortunately, it is also a major disruptor
of the gut microbiota, and has been shown to pro-
foundly alter the natural taxa in the GIT after only a
single course of treatment, with some taxa never
recolonizing.34 Our studies provide further support of
this indirect action of the antibiotic, as it led to a 1
log-reduction of the representative SI consortia in this
study. In contrast, the phage preparation only
impacted the E. coli populations, and had no impact
on any of the other six “commensal” bacterial species
included in our model.
The speciﬁcity of bacteriophages may offer some
important medical / health beneﬁts. For example, it
can help mitigate unnecessary bacterial diversity reduc-
tion (and potential dysbiosis) in the gut. While there is
a plethora of knowledge on microbial dysbiosis as it
relates to antibiotic treatments, there is less under-
standing on how phages may affect the microbiota. Of
the few studies examining phage therapy, none have
reported any adverse effects on human health, or major
alterations of the microbiome.17,18,35,36 The present
study corroborated those ﬁndings. Noteworthy, the
bacteriophage cocktail did also lyse a large number of
other E. coli strains in vitro; i.e., it was not solely lytic
for one targeted E. coli strain. Thus, the use of such
cocktail may still potentially impact some non-targeted
E. coli in the small intestine. However, the use of a
broad host range E. coli phage T4 (“broad host range”
deﬁned here as the ability of a given bacteriophage to
lyse several strains of the same bacteria species) has
been reported not to deleteriously change the normal
E. coli microbiota of human volunteers.16 Additional
studies, including larger scale trials in human volun-
teers, will be required to better elucidate the impact of
phage administration on the commensal microbiota.
Overall, our data support the idea that properly
selected phage preparations could be potentially at least
equally effective as a commonly prescribed antibiotic
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in reducing the E. coli levels in the small intestine, but
may have a signiﬁcantly milder impact on non-tar-
geted, “normal microbiota” bacteria.
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